Close
Smartlab Europe
Achema middle east

News

Aridis Is Enrolling Patients in Pivotal Trial of Its Antibiotic-resistant Pneumonia Therapy Aerucin

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody...

KALYDECO® ( ivacaftor ) Approved By FDA For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function...

Vertex Pharmaceuticals Incorporated announced that the U.S. FDA has approved KALYDECO® (ivacaftor) for use in more than 600 people with CF ages 2 and older who have one of five residual function mutations that result in a splicing defect...

Eisai Submits Simultaneous Applications in The United States and Europe for Lenvatinib in Hepatocellular Carcinoma

Eisai Co., Ltd. announced that it has submitted applications to the US FDA and the EMA for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC). This follows...

Lack Of Confidence In Serialization Preparations Highlighted By New Research

More than one third (40 per cent) of pharmaceutical industry professionals are not confident that they will meet serialization deadlines in the US and Europe, according to new industry research. As the FDA has announced plans...

Broad range of multifunctional mineral excipients  

At CPhI in Frankfurt, Omya will showcase its Omyapharm® multifunctional excipient platform based on functionalized calcium carbonate, a highly structured mineral. Omyapharm® is suitable for numerous applications, including solid oral dosage forms such as conventional tablets...

Technology adoption fuels growth for pharma tech firm

Zenith Technologies has strengthened its global workforce, recruiting 100 people over the past year in response to growing demand for manufacturing execution system (MES) and automation technology in the pharma sector. The global life science technology...

Onyx helps accelerate TopiVert’s compounds to clinic

BRITISH biotech business TopiVert has recently initiated clinical trials with two of its narrow spectrum kinase inhibitor (NSKI) drug candidates following support from Onyx Scientific. The contract research organisation (CRO) and small scale API specialist has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »